PMC:4627622 / 3877-4587 JSONTXT

{"project":"TEST0","denotations":[{"id":"26512021-226-232-1479076","span":{"begin":226,"end":228},"obj":"[\"25463029\"]"},{"id":"26512021-147-153-1479077","span":{"begin":424,"end":426},"obj":"[\"19539239\"]"},{"id":"26512021-151-157-1479078","span":{"begin":428,"end":430},"obj":"[\"9463456\"]"},{"id":"26512021-162-168-1479079","span":{"begin":595,"end":597},"obj":"[\"24754925\"]"},{"id":"26512021-166-172-1479080","span":{"begin":599,"end":601},"obj":"[\"16458930\"]"},{"id":"26512021-102-108-1479081","span":{"begin":706,"end":708},"obj":"[\"21054362\"]"}],"text":"Therefore, it is possible that candidates for targets of migraine treatment may reside outside the BBB; the dural vasculature, the trigeminal ganglion (TG) and in CNS regions lacking a BBB such as pituitary and pineal glands [15] and at nerve afferents that connect to the TG. The dural vasculature, including the middle meningeal artery (MMA) has long been considered as a target based on the vasogenic theory of migraine [16, 17]. We and others have shown that both sumatriptan and telcagepant can inhibit CGRP induced vasodilation in the human MMA, illustrating one of its potential targets [18, 19]. However, not all vasodilators cause migraine and triptans are not effective in all migraine patients [20]."}

{"project":"2_test","denotations":[{"id":"26512021-25463029-60534718","span":{"begin":226,"end":228},"obj":"25463029"},{"id":"26512021-19539239-60534719","span":{"begin":424,"end":426},"obj":"19539239"},{"id":"26512021-9463456-60534720","span":{"begin":428,"end":430},"obj":"9463456"},{"id":"26512021-24754925-60534721","span":{"begin":595,"end":597},"obj":"24754925"},{"id":"26512021-16458930-60534722","span":{"begin":599,"end":601},"obj":"16458930"},{"id":"26512021-21054362-60534723","span":{"begin":706,"end":708},"obj":"21054362"}],"text":"Therefore, it is possible that candidates for targets of migraine treatment may reside outside the BBB; the dural vasculature, the trigeminal ganglion (TG) and in CNS regions lacking a BBB such as pituitary and pineal glands [15] and at nerve afferents that connect to the TG. The dural vasculature, including the middle meningeal artery (MMA) has long been considered as a target based on the vasogenic theory of migraine [16, 17]. We and others have shown that both sumatriptan and telcagepant can inhibit CGRP induced vasodilation in the human MMA, illustrating one of its potential targets [18, 19]. However, not all vasodilators cause migraine and triptans are not effective in all migraine patients [20]."}